Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

Alan B. Sandler, J. Nemunaitis, C. Denham, J. Von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch Manegold, M. C. Palmer, A. Gregor, B. Nguyen, C. Niyikiza, Lawrence Einhorn

Research output: Contribution to journalArticle

639 Citations (Scopus)

Abstract

Purpose: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small- cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. Patients and Methods: Patients were randomized to receive either cisplatin (100 mg/m2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m2 intravenously on day 1) plus gemcitabine (1,000 mg/m2 administered intravenously on days 1, 8, and 15 of a 28-day cycle). Results: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25.4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004). Conclusions: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.

Original languageEnglish
Pages (from-to)122-130
Number of pages9
JournalJournal of Clinical Oncology
Volume18
Issue number1
StatePublished - Jan 2000

Fingerprint

gemcitabine
Non-Small Cell Lung Carcinoma
Cisplatin
Survival
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. / Sandler, Alan B.; Nemunaitis, J.; Denham, C.; Von Pawel, J.; Cormier, Y.; Gatzemeier, U.; Mattson, K.; Manegold, Ch; Palmer, M. C.; Gregor, A.; Nguyen, B.; Niyikiza, C.; Einhorn, Lawrence.

In: Journal of Clinical Oncology, Vol. 18, No. 1, 01.2000, p. 122-130.

Research output: Contribution to journalArticle

Sandler, AB, Nemunaitis, J, Denham, C, Von Pawel, J, Cormier, Y, Gatzemeier, U, Mattson, K, Manegold, C, Palmer, MC, Gregor, A, Nguyen, B, Niyikiza, C & Einhorn, L 2000, 'Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer', Journal of Clinical Oncology, vol. 18, no. 1, pp. 122-130.
Sandler, Alan B. ; Nemunaitis, J. ; Denham, C. ; Von Pawel, J. ; Cormier, Y. ; Gatzemeier, U. ; Mattson, K. ; Manegold, Ch ; Palmer, M. C. ; Gregor, A. ; Nguyen, B. ; Niyikiza, C. ; Einhorn, Lawrence. / Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. In: Journal of Clinical Oncology. 2000 ; Vol. 18, No. 1. pp. 122-130.
@article{fe58dae57879425b940026c0c00d2693,
title = "Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer",
abstract = "Purpose: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small- cell lung cancer (NSCLC), the response rate was 33{\%}, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. Patients and Methods: Patients were randomized to receive either cisplatin (100 mg/m2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m2 intravenously on day 1) plus gemcitabine (1,000 mg/m2 administered intravenously on days 1, 8, and 15 of a 28-day cycle). Results: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3{\%} of patients compared with 1.2{\%} of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5{\%} in both arms. Grade 4 thrombocytopenia occurred in 25.4{\%} of patients on the combination arm compared with 0.8{\%} of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4{\%} compared with 11.1{\%}, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004). Conclusions: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.",
author = "Sandler, {Alan B.} and J. Nemunaitis and C. Denham and {Von Pawel}, J. and Y. Cormier and U. Gatzemeier and K. Mattson and Ch Manegold and Palmer, {M. C.} and A. Gregor and B. Nguyen and C. Niyikiza and Lawrence Einhorn",
year = "2000",
month = "1",
language = "English",
volume = "18",
pages = "122--130",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

AU - Sandler, Alan B.

AU - Nemunaitis, J.

AU - Denham, C.

AU - Von Pawel, J.

AU - Cormier, Y.

AU - Gatzemeier, U.

AU - Mattson, K.

AU - Manegold, Ch

AU - Palmer, M. C.

AU - Gregor, A.

AU - Nguyen, B.

AU - Niyikiza, C.

AU - Einhorn, Lawrence

PY - 2000/1

Y1 - 2000/1

N2 - Purpose: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small- cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. Patients and Methods: Patients were randomized to receive either cisplatin (100 mg/m2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m2 intravenously on day 1) plus gemcitabine (1,000 mg/m2 administered intravenously on days 1, 8, and 15 of a 28-day cycle). Results: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25.4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004). Conclusions: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.

AB - Purpose: The Hoosier Oncology Group has previously reported the results of its phase II trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients with advanced or metastatic non-small- cell lung cancer (NSCLC), the response rate was 33%, with a median survival of 8.4 months. Based on such favorable results, the Hoosier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared with cisplatin alone in chemotherapy-naive patients with advanced NSCLC. Patients and Methods: Patients were randomized to receive either cisplatin (100 mg/m2 intravenously on day 1 of a 28-day cycle) or the combination of cisplatin (100 mg/m2 intravenously on day 1) plus gemcitabine (1,000 mg/m2 administered intravenously on days 1, 8, and 15 of a 28-day cycle). Results: From August 1995 to February 1997, 522 assessable chemotherapy-naive patients were randomized. Toxicity was predominantly hematologic and was more pronounced in the combination arm, with grade 4 neutropenia occurring in 35.3% of patients compared with 1.2% of patients on the cisplatin monotherapy arm. The incidence of neutropenic fevers was less than 5% in both arms. Grade 4 thrombocytopenia occurred in 25.4% of patients on the combination arm compared with 0.8% of patients on the cisplatin monotherapy arm. No serious hemorrhagic events related to thrombocytopenia were reported for either arm. The combination of gemcitabine plus cisplatin demonstrated a significant improvement over single-agent cisplatin with regard to response rate (30.4% compared with 11.1%, respectively; P < .0001), median time to progressive disease (5.6 months compared with 3.7 months, respectively; P = .0013), and overall survival (9.1 months compared with 7.6 months, respectively; P = .004). Conclusions: For the first-line treatment of NSCLC, the regimen of gemcitabine plus cisplatin is superior to cisplatin alone in terms of response rate, time to disease progression, and overall survival.

UR - http://www.scopus.com/inward/record.url?scp=17344384668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17344384668&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 122

EP - 130

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -